Overview

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

Status:
Terminated
Trial end date:
2020-05-19
Target enrollment:
Participant gender:
Summary
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
Phase:
Phase 2
Details
Lead Sponsor:
Aurinia Pharmaceuticals Inc.
Treatments:
Cyclosporine